Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RN7SK pseudogene 221 (RN7SKP221) is classified as a pseudogene, which means it is a genomic sequence similar to the functional RN7SK gene but lacks the ability to produce a functional RNA or protein product. Pseudogenes generally result from gene duplication or retrotransposition and acquire disabling mutations that prevent their expression or function. There is currently no evidence that RN7SKP221 acts as a receptor, enzyme, transporter, or any other pharmacologically actionable molecule. RN7SKP221 should not be confused with the functional RN7SK gene (small nuclear RNA 7SK), which has important roles in transcriptional regulation and immune functions, but the pseudogene itself is not considered a therapeutic target nor does it play a role in disease states or drug interactions[3][5]. The entry "RN7SKP221" is incorrect or incomplete for therapeutic target analysis, as it refers to a non-functional pseudogene. If you intended to reference the functional molecule, you should search for "RN7SK small nuclear RNA" or "small nuclear RNA 7SK" instead.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RN7SK pseudogene 221 (RN7SKP221).